PL2758071T3 - Terapia szczepionkowa - Google Patents

Terapia szczepionkowa

Info

Publication number
PL2758071T3
PL2758071T3 PL12772616T PL12772616T PL2758071T3 PL 2758071 T3 PL2758071 T3 PL 2758071T3 PL 12772616 T PL12772616 T PL 12772616T PL 12772616 T PL12772616 T PL 12772616T PL 2758071 T3 PL2758071 T3 PL 2758071T3
Authority
PL
Poland
Prior art keywords
vaccine therapy
vaccine
therapy
Prior art date
Application number
PL12772616T
Other languages
English (en)
Inventor
Andrea Pfeifer
Andreas Muhs
Rime MADANI
Pavel Vasilyevich BELICHENKO
William Charles Mobley
Original Assignee
Ac Immune S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ac Immune S.A. filed Critical Ac Immune S.A.
Publication of PL2758071T3 publication Critical patent/PL2758071T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL12772616T 2011-09-23 2012-09-21 Terapia szczepionkowa PL2758071T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
USPCT/US2011/052992 2011-09-23
EP12772616.4A EP2758071B1 (en) 2011-09-23 2012-09-21 Vaccine therapy
PCT/US2012/056728 WO2013044147A1 (en) 2011-09-23 2012-09-21 Vaccine therapy

Publications (1)

Publication Number Publication Date
PL2758071T3 true PL2758071T3 (pl) 2019-08-30

Family

ID=47018510

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12772616T PL2758071T3 (pl) 2011-09-23 2012-09-21 Terapia szczepionkowa

Country Status (23)

Country Link
US (2) US20140314837A1 (pl)
EP (1) EP2758071B1 (pl)
JP (1) JP6110861B2 (pl)
KR (3) KR20160099732A (pl)
CN (2) CN104039346A (pl)
AU (1) AU2012312126B2 (pl)
BR (1) BR112014006871A2 (pl)
CA (1) CA2811188C (pl)
DK (1) DK2758071T3 (pl)
EA (1) EA032494B1 (pl)
ES (1) ES2712951T3 (pl)
HU (1) HUE041277T2 (pl)
IL (1) IL231564A0 (pl)
MX (1) MX350928B (pl)
MY (1) MY169574A (pl)
PH (1) PH12014500657A1 (pl)
PL (1) PL2758071T3 (pl)
PT (1) PT2758071T (pl)
SG (1) SG11201400795UA (pl)
SI (1) SI2758071T1 (pl)
TR (1) TR201901846T4 (pl)
WO (1) WO2013044147A1 (pl)
ZA (1) ZA201402071B (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2885010B1 (en) 2012-08-16 2020-01-01 Ipierian, Inc. Methods of treating a tauopathy
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
CN105939722A (zh) 2014-02-14 2016-09-14 伊皮埃里安股份有限公司 Tau肽,抗Tau抗体,及其使用方法
MA41101A (fr) * 2014-12-03 2017-10-10 Lilly Co Eli Dispositif d'injection de médicament automatique comportant une indication audible de progression d'injection
TW202333768A (zh) 2017-10-25 2023-09-01 美商健生醫藥公司 Tau胜肽之組成物及其用途
CA3118692A1 (en) 2018-11-06 2020-05-14 Alsatech, Inc. Cell-based gene therapy for neurodegenerative diseases
SG11202108312PA (en) 2019-02-08 2021-08-30 Ac Immune Sa Method of safe administration of phosphorylated tau peptide vaccine
CN113853214A (zh) * 2019-05-21 2021-12-28 Ac免疫有限公司 抗Aβ疫苗治疗
WO2024156912A1 (en) 2023-01-26 2024-08-02 Ac Immune Sa Anti-abeta vaccine therapy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999009831A1 (en) 1997-08-28 1999-03-04 Ajay North America Methods and compositions for protecting plants and crops
KR20050101537A (ko) 2002-12-24 2005-10-24 뉴로켐 (인터내셔널) 리미티드 베타-아밀로이드 관련 질환의 치료를 위한 치료 제제
KR20050118669A (ko) * 2003-02-01 2005-12-19 뉴랄랩 리미티드 가용성 a-베타에 대한 항체를 생성하기 위한 능동 면역화
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
SI2336147T1 (sl) * 2003-12-17 2014-08-29 Janssen Alzheimer Immunotherapy Konjugati nosilcev a beta imunogenih peptidov in postopki izdelave istih
AU2005290250A1 (en) * 2004-07-30 2006-04-06 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
CA2633399C (en) * 2005-12-12 2016-01-26 Ac Immune S.A. Therapeutic vaccine
CA2690434C (en) * 2007-06-12 2018-05-22 Ac Immune S.A. Monoclonal anti beta amyloid antibody
MX2011009654A (es) * 2009-03-18 2011-10-12 Ac Immune Sa Metodo para uso terapeutico.
EP2632434B1 (en) * 2010-10-26 2025-08-20 AC Immune S.A. Liposome-based construct comprising a peptide modified through hydrophobic moieties

Also Published As

Publication number Publication date
EP2758071A1 (en) 2014-07-30
EA201400376A1 (ru) 2014-09-30
US20140314837A1 (en) 2014-10-23
EA032494B1 (ru) 2019-06-28
JP2014531455A (ja) 2014-11-27
WO2013044147A1 (en) 2013-03-28
HUE041277T2 (hu) 2019-05-28
AU2012312126A1 (en) 2014-03-27
PT2758071T (pt) 2019-01-11
CN109847058A (zh) 2019-06-07
JP6110861B2 (ja) 2017-04-05
ES2712951T3 (es) 2019-05-16
PH12014500657A1 (en) 2014-05-05
IL231564A0 (en) 2014-04-30
AU2012312126B2 (en) 2016-11-10
CA2811188A1 (en) 2013-03-23
MY169574A (en) 2019-04-22
DK2758071T3 (en) 2019-02-18
MX2014003325A (es) 2014-05-21
KR20160005380A (ko) 2016-01-15
NZ622653A (en) 2015-12-24
CA2811188C (en) 2020-04-28
SG11201400795UA (en) 2014-10-30
ZA201402071B (en) 2017-08-30
BR112014006871A2 (pt) 2017-04-04
TR201901846T4 (tr) 2019-03-21
SI2758071T1 (sl) 2019-01-31
US20240270829A1 (en) 2024-08-15
KR102129220B1 (ko) 2020-07-02
MX350928B (es) 2017-09-26
KR20190035948A (ko) 2019-04-03
CN104039346A (zh) 2014-09-10
KR20160099732A (ko) 2016-08-22
EP2758071B1 (en) 2018-11-28

Similar Documents

Publication Publication Date Title
ZA201305897B (en) Combination therapy
IL235890A0 (en) vaccine
ZA201400120B (en) Combination therapy
GB201223386D0 (en) Vaccine
IL231043A (en) vaccine
PL2489413T3 (pl) Przyrząd terapeutyczny
ZA201402071B (en) Vaccine therapy
ZA201502595B (en) Therapeutic methods
GB201119999D0 (en) Vaccine
EP2701744A4 (en) COMBINATION THERAPY
GB201207305D0 (en) Therapy
ZA201306245B (en) Combination vaccines
IL228589A0 (en) Medical Care
GB201120000D0 (en) Vaccine
GB201210226D0 (en) Vaccine
GB201202090D0 (en) Vaccine
GB201102913D0 (en) Novel therapeutic
GB201121647D0 (en) Vaccine
GB201108256D0 (en) Vaccine
GB201120096D0 (en) Novel therapy
GB201114226D0 (en) Combination therapy
GB201107549D0 (en) Cancer vaccine
GB201110895D0 (en) Therapeutic use
GB201109294D0 (en) Novel vaccine
GB201108984D0 (en) Vaccines